Dr. Abdulkareem Algarni, MD Consultant Hematology, KAH/MNGHA, Eastern Region, SA Assistant professor of Hematology/oncology at KSAU-HS, talks about the translating data into clinical practice. Dr. Abdulkareem Algarni initially discusses about CLL case report and indication for initiating treatment. As a continuation for this he explained how to select the first line therapy by analyzing the survival outcomes and comparisons based on IGHV mutation status. Also explained the comparison of PFS between ELEVTE TN, CLL14 and ILLUMINATE trial. Side effects of BTKi discusses by taking ELEVATE RR study and survival outcomes, reported adverse events mentioned. Dr. Abdulkareem Algarni initially considering all these points are added in the case report.

 

 

Explore more videos

Configure Image Component

Critical Evaluation of BTKis in CLL

Dr. George Follows, UK

Configure Image Component

Evolvement of CLL Management

Dr. Mahmoud Marashi, UAE

Configure Image Component

CLL Management Inside the Clinic

Dr. Hani Yousif Osman , UAE

Modal Window Component Section Begins
Modal Window Component Section Ends